A single-blind, randomised controlled trial on the effects of lithium and quetiapine monotherapy on the trajectory of cognitive functioning in first episode mania: A 12-month follow-up study.

Détails

ID Serval
serval:BIB_78579F31AC50
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
A single-blind, randomised controlled trial on the effects of lithium and quetiapine monotherapy on the trajectory of cognitive functioning in first episode mania: A 12-month follow-up study.
Périodique
European Psychiatry
Auteur(s)
Daglas R., Cotton S.M., Allott K., Yücel M., Macneil C.A., Hasty M.K., Murphy B., Pantelis C., Hallam K.T., Henry L.P., Conus P., Ratheesh A., Kader L., Wong M.T., McGorry P.D., Berk M.
ISSN
1778-3585 (Electronic)
ISSN-L
0924-9338
Statut éditorial
Publié
Date de publication
2016
Peer-reviewed
Oui
Volume
31
Pages
20-28
Langue
anglais
Résumé
BACKGROUND: Cognitive deficits have been reported during the early stages of bipolar disorder; however, the role of medication on such deficits remains unclear. The aim of this study was to compare the effects of lithium and quetiapine monotherapy on cognitive performance in people following first episode mania.
METHODS: The design was a single-blind, randomised controlled trial on a cohort of 61 participants following first episode mania. Participants received either lithium or quetiapine monotherapy as maintenance treatment over a 12-month follow-up period. The groups were compared on performance outcomes using an extensive cognitive assessment battery conducted at baseline, month 3 and month 12 follow-up time-points.
RESULTS: There was a significant interaction between group and time in phonemic fluency at the 3-month and 12-month endpoints, reflecting greater improvements in performance in lithium-treated participants relative to quetiapine-treated participants. After controlling for multiple comparisons, there were no other significant interactions between group and time for other measures of cognition.
CONCLUSION: Although the effects of lithium and quetiapine treatment were similar for most cognitive domains, the findings imply that early initiation of lithium treatment may benefit the trajectory of cognition, specifically verbal fluency in young people with bipolar disorder. Given that cognition is a major symptomatic domain of bipolar disorder and has substantive effects on general functioning, the ability to influence the trajectory of cognitive change is of considerable clinical importance.
Mots-clé
Adolescent, Adult, Antimanic Agents/therapeutic use, Antipsychotic Agents/therapeutic use, Bipolar Disorder/drug therapy, Bipolar Disorder/psychology, Cognition/drug effects, Dibenzothiazepines/therapeutic use, Female, Follow-Up Studies, Humans, Intelligence, Lithium Compounds/therapeutic use, Male, Memory, Quetiapine Fumarate/therapeutic use, Single-Blind Method, Time Factors, Treatment Outcome, Verbal Learning, Young Adult
Pubmed
Web of science
Création de la notice
19/02/2016 19:08
Dernière modification de la notice
20/08/2019 15:35
Données d'usage